Long Term Patient Reported Urinary Function Following External Beam Radiotherapy for Prostate Cancer

Chin, Stephen; Hayden, Alix; Gebski, Val; Cross, Shane; Turner, Sandra

doi:10.1016/j.clon.2017.01.043

Cited by 7 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite radiation therapy conferring a similar oncological outcome to that of RARP [35], worse long-term LUTS after radiation therapy [36] appear to play a significant role in PCa survivorship and treatment selection. The available published data on IPSS post RARP vs post radiation therapy for localized PCa are summarized in Table 4 [37][38][39]. While these are non-randomized, cross-cohort comparisons, mean post-treatment IPSSs were worse for radiation therapy, with less improvement in all three subgroups of baseline mild, moderate and severe LUTS when compared with our RARP cohort observed for both intensity-modulated radiation therapy and external beam radiation therapy.…”

Section: Discussionmentioning

confidence: 76%

Improved lower urinary tract symptoms after robot‐assisted radical prostatectomy: implications for survivorship, treatment selection and patient counselling

et al. 2019

View full text Add to dashboard Cite

ObjectiveTo assess changes in lower urinary tract symptoms (LUTS) and quality of life (QoL) after robot-assisted radical prostatectomy (RARP). Patients and MethodsA prospectively curated database of 1917 consecutive RARPs undertaken over an 8-year period from January 2009 to January 2017 was assessed. Preoperative information including age, prostate-specific antigen (PSA) level, body mass index (BMI), International Prostate Symptom Score (IPSS) and QoL score was collected, with IPSS and QoL score compared between baseline (preoperatively) and 12 months post-surgery. ResultsOf the 1917 patients who underwent RARP, 1470 with complete data were included in the analysis. Their mean AE SD age, prostate weight and BMI were 62 (AE6.7) years, 51 (AE17.6) g, and 28 kg/m 2 , respectively. Overall, 57% of patients reported an improved IPSS score, whilst 76% reported an IPSS of ≤7 postoperatively. A total of 41% of patients reported an improved QoL and 90.3% of patients with severe preoperative LUTS (IPSS 20-35) demonstrated clinically improved LUTS at 1 year post RARP. The post-RARP mean IPSS in the present study was lower than those reported in the existing post-radiotherapy literature, especially in patients with moderate to severe baseline LUTS (IPSSs ≥ 8). ConclusionsAt 12 months post RARP, most patients reported improved overall LUTS and QoL, with the greatest benefit seen in those patients with a high pre-RARP IPSS. This has implications for treatment selection and preoperative counselling in men being offered active treatment for their prostate cancer. Further analyses of specific IPSS domains and longer followup are needed. KeywordsInternational Prostate Symptom Score, lower urinary tract symptoms, prostate cancer, quality of life, robot-assisted radical prostatectomy, survivorship Abbreviations: QoL, quality of life; RARP, robot-assisted radical prostatectomy; PCa, prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 76%

Improved lower urinary tract symptoms after robot‐assisted radical prostatectomy: implications for survivorship, treatment selection and patient counselling

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This tool consists of seven symptoms (frequency, nocturia, weak urinary stream, hesitancy, intermittency, incomplete emptying and urgency) and one urinary quality of life question. Each symptom is scored from 0 to 5, with the total IPSS being the total of all seven symptom scores 27 . The IPSS tool is particularly advantageous during radiotherapy as it is patient reported and can give a more accurate indicator of change in urinary function as treatment progresses.…”

Section: Crr Role Developmentmentioning

confidence: 99%

“…Each symptom is scored from 0 to 5, with the total IPSS being the total of all seven symptom scores. 27 The IPSS tool is particularly advantageous during radiotherapy as it is patient reported and can give a more accurate indicator of change in urinary function as treatment progresses. CRRs have expert knowledge working with quality of life tools that are used in prostate cancer trials.…”

Section: Crr Role Developmentmentioning

confidence: 99%

Evaluating the effectiveness of the clinical research radiographer undertaking the on-treatment review of clinical trial patients receiving radiotherapy for prostate cancer

Murray

Gilleece²,

Flood³

2018

J Radiother Pract

View full text Add to dashboard Cite

BackgroundRadiotherapy clinical trials are at the forefront of modern-day prostate cancer patient management. Patients are reviewed during treatment by clinical oncologists or competent on-treatment review radiographers to minimise treatment toxicities. Clinical Research Radiographers (CRRs) routinely monitor and gather research data from patients participating in clinical trials.PurposeThe aim of this article is to evaluate the effectiveness of the CRR undertaking the on-treatment review of clinical trial patients.MethodAn experienced CRR within the Northern Ireland Cancer Trials Network was supervised by a clinical oncologist to undertake the role of the on-treatment review of patients receiving radiotherapy for prostate cancer. The CRR explored published literature and compiled this written evaluation as part of their advanced practice learning.ResultsThe supervising clinical oncologist verified, following the planned period of supervised practice and academic study, that the CRR was competent to fulfil the role. Evidence of the beneficial synergistic impact of co-joining the roles was experienced at first hand during the undertaking of supervised practice.ConclusionCo-joining the roles and responsibilities of the CRR and the on-treatment review radiographer enhanced the quality of care offered to the patients participating in clinical trials.

show abstract

“…For patients suffering from prostate cancer (PCa), several treatment modalities are available (1)(2)(3). An important aspect of counseling patients is to understand the impact of each management option on their quality of life (QoL) (4,5). Some of these treatments, such as androgen deprivation therapy (ADT) have positive effects on QoL that improve the QoL of patients with moderate to severe voiding dysfunction via decreasing prostate volume and lower urinary tract symptoms (LUTS) (3,6).…”

Section: Introductionmentioning

confidence: 99%

Post Intensity-Modulated Radiation Therapy Urinary Function for Prostate Cancer; A Prospective Study

et al. 2020

View full text Add to dashboard Cite

Background: At present, there is a lack of evidence concerning urinary complications caused by intensity-modulated radiation therapy (IMRT) used for the management of prostate cancer (PCa). Objectives: This study aimed at identifying the nature and severity of post-IMRT urinary symptoms in patients with PCa. Methods: This prospective study was performed with consecutive patients, who had clinically localized PCa (cT1c-cT2c) and had undergone IMRT treatment from 2016 to 2019. At 1, 6, and 12 months of follow-up, medical history, physical information, prostate-specific antigen values, International Prostate Symptom Score (IPSS), medication use, Radiation Therapy Oncology Group (RTOG), acute and late toxicity, and Q max were collected. Results: A total of 127 patients with a mean age of 71.04 ± 7.1 years received IMRT and underwent 12 months of follow-up. The mean IPSSs at baseline versus those at 1, 6, and 12 months after IMRT was 14.5 ± 6.8 versus 13.3 ± 6.1, 12.3 ± 5.3, and 10.4 ± 4.2, respectively (P < 0.000). The mean prostate volume was 38.2 ± 12.1 cc. At the last follow-up, 31 patients (24.4%) took genitourinary (GU) medications. Conclusions: This study showed that the majority of GU side effects caused by primary IMRT for PCa treatment are transient. Treatment triggered an acute increase in obstructive urinary symptoms, which peaked during the first month after IMRT. In most patients, in the course of 6 months, symptoms returned to baseline.

show abstract

Long Term Patient Reported Urinary Function Following External Beam Radiotherapy for Prostate Cancer

Cited by 7 publications

References 27 publications

Improved lower urinary tract symptoms after robot‐assisted radical prostatectomy: implications for survivorship, treatment selection and patient counselling

Improved lower urinary tract symptoms after robot‐assisted radical prostatectomy: implications for survivorship, treatment selection and patient counselling

Evaluating the effectiveness of the clinical research radiographer undertaking the on-treatment review of clinical trial patients receiving radiotherapy for prostate cancer

Post Intensity-Modulated Radiation Therapy Urinary Function for Prostate Cancer; A Prospective Study

Contact Info

Product

Resources

About